In our work, we tested the in vitro efficacy of GANT61 (a GLI-inhibitor) and demonstrated that this treatment could affect the viability of GIST cells and modulate the expression of key genes for tumor progression, such KIT and CDKN1A. The gene discussed is GLI1; the disease is neoplasm.